Decay in the glyceroldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease

M Kitamura, N Kitaichi, M Takeuchi, H Kitamei, K Namba, S-i Yamagishi, K Iwabuchi, K Onoé, S Ohno

Background/aims: Advanced glycation end products (AGEs) are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceroldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease.

Methods: Sera were obtained from 31 patients with active VKH. Twenty of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody.

Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 [2.94], p<0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p<0.001).

Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.

VKH disease is a bilateral, granulomatous panuveitis often associated with such extraocular organs as the auditory system, meninges, and the skin. The results of earlier studies indicated that VKH disease is a cell mediated autoimmune disorder which acts against melanocytes. As a result the melanocytes of every organ could be affected by this disease. As a genetic factor, both our colleagues and others have previously reported VKH disease to be closely related to some HLA haplotypes such as HLA-DRB1*0405, DRB1*0410, DQA1*03 and DQB1*04. However, some patients develop VKH disease even without demonstrating such HLA haplotypes. Since HLA typing does not greatly contribute to the diagnosis, today such patients are commonly treated with systemic corticosteroids.

Advanced glycation end products (AGEs) and Maillard reaction products are permanently modified protein derivatives which form in the presence of reducing sugars, such as glucose and fructose by non-enzymatic glycation, oxidation reactions, and further irreversible rearrangements in vivo and in heat treated food. AGEs are thus suggested to have a role in the diabetic complications of retinopathy and nephropathy, as well as the age related pathologies such as Alzheimer’s disease, a decreased skin elasticity, male erectile dysfunction, pulmonary fibrosis, and atherosclerosis. Although only a few scientists have so far focused on Maillard chemistry over the past five decades after its discovery, food scientists recently recognised that non-enzymatic glycation has an important role in food flavour, aroma, and nutritional bioavailability. The Maillard reaction has so far only been partially characterised, and the structures of some AGEs generated in vivo have never even been determined. Six distinct AGE classes (designated as AGE-1 to AGE-6) have been reported in the serum of diabetic patients.

Recent studies have demonstrated that the receptor for AGE (RAGE) is expressed in human melanoma cells, and glyceroldehyde derived AGE (AGE-2) and glycolaldehyde derived AGE (AGE-3), but not other subtypes of AGEs, can thus upregulate the growth and migration of human melanoma cells. More recently, it was indicated that AGEs should be classified as non-toxic (N-carboxymethyllysine, pentosidine, etc) and toxic (AGE-2, AGE-3, etc); the latter are considered to be important in the pathophysiological processes of AGE formation. In this study, we hypothesised that if AGE-RAGE interactions can enhance the growth of melanoma cells, then low levels of AGE-2 might be detected in the sera of patients with acute VKH disease, an autoimmune disease against systemic melanocytes. Even if the AGEs are related to immunological tolerance to melanocytes, the level of AGEs should increase again after the treatment of VKH disease.

Patients and methods

Thirty one patients with acute VKH who visited the uveitis survey clinic of Hokkaido University Hospital between 2000 and 2003 were examined. Each patient met the diagnostic criteria for VKH disease. They consisted of 13 men and 18 women, and their mean age was 42.7 (SD 15.2) years old (range 15–74 years old) at their first visits. None of them had previously received systemic corticosteroid agents. Thirty three age matched healthy volunteers served as controls. Although some of the patients received topical corticosteroid therapy, no subjects were treated with either systemic corticosteroids or immunosuppressive agents. After the diagnosis of VKH disease, all 31 patients received high dose corticosteroid therapy, starting with prednisolone 200 mg.

Among the VKH patients there were three with diabetes mellitus without diabetic complications. No other systemic diseases were detected.

After obtaining informed consent in accordance with the tenets of the Declaration of Helsinki, sera were collected from 31 VKH patients with acute panuveitis (mean age 42.7 (SD 15.2) years old) and 33 (14 men and 19 women) healthy volunteers (37.1 (11.5)). We also collected the sera from seven men and...
13 women (46.4 (12.8) years old) of 31 VKH patients 4 weeks after being treated with systemic corticosteroids. None of the VKH patients demonstrated either ocular or systemic inflammation at the time.

The serum levels of AGE-2 were measured with a competitive enzyme linked immunosorbent assay (ELISA), as described previously. The results are expressed in AGE-2 units (U)/ml of the serum, with 1 U defined as the amount of AGE-2 antibody reactive materials that caused competition in ELISA to the same extent as did 1 µg of AGE-2-BSA standard. The same set of experiments was repeated three times and the results were averaged. Moreover, we also studied the fasting plasma glucose levels of 23 out of 31 VKH patients both at the acute stage before systemic corticosteroid therapy and at the convalescent stage under systemic medication to consider the effects of the fasting plasma glucose levels on the serum level of AGE-2. A statistical analysis was performed using Mann-Whitney U test or paired t test.

RESULTS

The mean serum levels of AGE-2 were measured as 4.91 (SD 2.23) U/ml in acute VKH patients and 8.32 (2.94) U/ml in healthy control subjects. The average level of AGE-2 in the sera of acute stage VKH patients (4.91 (2.23)) was significantly lower than that of the healthy control subjects (8.32 (2.94)) (p<0.001). Statistical analysis was performed using Mann-Whitney U test.

Hyperglycaemia is a major cause for an increased serum AGE-2 level, because AGEs are the “end products” of glycation. To investigate whether the low levels of serum AGE-2 in VKH disease was associated with blood glucose levels, we next measured their fasting plasma glucose levels.

The fasting plasma glucose levels of VKH patients were 109.8 (51.5) mg/dl at the acute stage and 81.5 (21.2) mg/dl at the convalescent stage. Although fasting plasma glucose level was significantly higher at the acute stage than at the convalescent stage in VKH patients (p<0.01 by paired t test), the levels were considered to be normal during the study period (fig 3).
DISCUSSION
The formation of advanced glycation end products (AGEs) is considered to be a key pathophysiological event with links to a range of important human diseases, and AGEs may act as mediators, not only of diabetic complications but also of widespread age related pathologies. AGEs have also been implicated in the development of some neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Besides these diseases, AGEs have also been regarded as an important pathological event in diabetic and age related ocular diseases. AGEs have been characterised as belonging to distinct classes such as AGE-1 to AGE-6, and their different cell mediated responses have recently been reported. In the present study, we focused on the serum AGE-2 levels of acute VKH patients, because AGE-2 showed a direct toxic effect in vitro.

In this report, we demonstrated quite low levels of AGE-2 in the sera of patients with VKH disease at the exacerbation stage, and the levels also increased during the course of recovery. VKH disease is attributed to the destruction of melanocytes through immunological mechanisms, and antibodies and T cells specific for melanoma cells are also frequently detected, as well as normal melanocytes in VKH patients. Moreover, some patients have been reported to develop VKH disease following surgical treatment for malignant melanomas. While some other patients with melanoma, vitiligo has been reported to develop either spontaneously or following immunotherapy. The laboratory data of VKH patients have also sometimes been described to be completely different from those with malignant melanoma. Though it is possible that AGE-RAGE interactions are involved in the onset of VKH disease besides malignant melanoma, further studies are needed to clarify their mechanisms of action. Experimental autoimmune anterior uveitis (EAU) is an animal model for human endogenous uveitis induced by melanin associated proteins. If the AGE-RAGE interactions contribute to the destruction and/or proliferation of melanocytes in vivo, a study to modulate EAU by varying the AGE-2 concentrations may thus help to explain the present results.

As reported elsewhere, most patients with VKH disease demonstrate glucose intolerance at onset of the disease; thereafter, such glucose tolerance tended to recover after treatment with systemic corticosteroids. It is thus reasonable that we detected high levels of fasting plasma glucose at the acute phase of the disease, and its decrease was able that we detected high levels of fasting plasma glucose at the onset of some autoimmune diseases, this is the first report to show the dramatic decrease in the serum AGE-2 levels at the exacerbation stage of VKH, and the increase in those levels after recovery. It is thus reasonable that the AGE-2 associated mechanisms might therefore be involved in the onset of VKH disease. 

ACKNOWLEDGEMENTS
This study was supported in part by a grant for research on sensory and communicative disorders from the Ministry of Health, Labor, and Welfare Japan, and by grants in aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan.

Authors’ affiliations
M Kitamura, N Kitaichi, H Kimatei, K Namba, S Ohno, Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan
M Takeuchi, Department of Pathophysiological Science, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan
T Yamagishi, Department of Medicine III, Kurume University School of Medicine, Kurume, Japan
M Kitamura, H Kimatei, K Ibawuchi, K Oono, Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
Correspondence to: Mizuki Kitamura, MD, Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Kita 15, Nishi 7, Kitaku, Sapporo 060-8638, Japan; mizukita825@ybb.ne.jp

Accepted for publication 1 July 2005

REFERENCES
Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease

M Kitamura, N Kitaichi, M Takeuchi, H Kitamei, K Namba, S-i Yamagishi, K Iwabuchi, K Onoé and S Ohno

Br J Ophthalmol 2005 89: 1407-1409
doi: 10.1136/bjo.2005.072678

Updated information and services can be found at:
http://bjo.bmj.com/content/89/11/1407

These include:

References
This article cites 22 articles, 9 of which you can access for free at:
http://bjo.bmj.com/content/89/11/1407#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Choroid (565)
Neurology (1355)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/